Stryker (SYK -3.80%), a leading global medical technology company, reported financial results on July 31, 2025. The company delivered several key beats: Net sales (GAAP) reached $6.0 billion, topping analyst expectations of $5.94 billion (GAAP), and adjusted earnings per share (non-GAAP) came in at $3.13, ahead of the $3.07 non-GAAP consensus. This performance reflected double-digit growth in both sales and profits compared to the same period last year. Stryker also raised its full-year 2025 guidance for or ...

Key Takeaways SYK Q2 revenue is expected to grow 9.9% to $5.96B, with EPS rising 8.9% to $3.06.SYK's Mako and MedSurg businesses likely drove growth, aided by new product rollouts and pricing.SYK faces early impact from tariffs, with $200M full-year cost expected to intensify in H2 2025.Stryker Corporation (SYK) is scheduled to release second-quarter 2025 results on July 31, after market close. In the last reported quarter, the company delivered an earnings surprise of 4.03%.Q2 EstimatesThe Zacks Consensus ...